pt2 shp53 gfp4  (Addgene inc)

Journal: Disease Models & Mechanisms

Article Title: Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAs

doi: 10.1242/dmm.052370

Figure Lengend Snippet: siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / shp53 HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.

Article Snippet: T/Caggs-NRASV12 ( Addgene plasmid #20205 ) and pT2/shp53/GFP4 ( Addgene plasmid #20208 ) were gifts from John Ohlfest (University of Minnesota, MN, USA).

Techniques: Injection

Journal: Cell

Article Title: A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence.

doi: 10.1016/j.cell.2024.06.019

Figure Lengend Snippet: Figure 4. SNORA13 regulates p53 activity through the nucleolar stress response pathway (A) Gene set enrichment analysis (GSEA) showing downregulation of the p53 pathway in SNORA13 knockout BJ-HRASG12V cells at baseline or after tamoxifen treatment. (B) RT-qPCR analysis of CDKN1A expression relative to GAPDH in wild-type BJ-HRASG12V cells or four independent SNORA13 knockout clones at baseline or after tamoxifen treatment. (legend continued on next page)

Article Snippet: Male FVB/NJ mice were injected at 7 weeks of age with pT/Caggs-NRASV12 (Addgene #20205),80 SB100 transposase plasmid (pCMV-SB100), and either 1) sgControl plasmid (sgGFP/sgGal4), 2) SNORA13 homolog targeting pool 1 plasmids, 3) SNORA13 homolog targeting pool 2 plasmids, or 4) a Sleeping Beauty plasmid expressing short-hairpin RNA targeting p53 (pT2/shp53/GFP4; Addgene #20208).80 Plasmids were resuspended in 2 mL of saline and administered via tail vein injection in 7 seconds.

Techniques: Activity Assay, Knock-Out, Quantitative RT-PCR, Expressing, Clone Assay